Executive Buying Newsletter June 1, 2026

Adding Positions in Tech, Growth, and Healthcare

We are adding the following positions to our semi-monthly model newsletter portfolio. Each offers compelling risk/reward in the current environment of AI leadership, small-cap rotation, and innovation-driven growth. Below is a concise breakdown for each.

ORCL (Oracle) Oracle remains a top AI infrastructure play with accelerating cloud revenue and massive backlog growth from hyperscaler partnerships. The company continues to benefit from strong demand for its OCI (Oracle Cloud Infrastructure) platform, positioning it as a key enabler of enterprise AI deployments. With analysts highlighting it as a standout software pick for 2026 and upcoming earnings on June 10, we recommend adding ORCL for exposure to high-margin cloud and AI tailwinds.

IBM IBM surged sharply today on Barclays initiating with an Overweight rating and a $350 price target, citing stable software growth and exciting quantum computing optionality. The company is following an "Nvidia-like playbook" in quantum while delivering consistent revenue gains. With strong momentum in AI, hybrid cloud, and quantum investments, IBM offers a more defensive tech profile with significant upside catalysts.

AAPL (Apple) Apple continues to trade near record territory with solid YTD performance, supported by AI enhancements expected at WWDC and ongoing ecosystem strength. While iPhone momentum has been mixed, the company’s services growth, on-device AI strategy, and potential Siri revamp provide a clear path forward. We view AAPL as a high-quality core holding in any long-term tech allocation.

TSLA (Tesla) Tesla remains a high-conviction growth name driven by robotaxi progress, Optimus robot development, and energy storage expansion. Despite near-term EV competition and volatility, the company’s AI/autonomy bets and production ramps position it for multi-year upside. We add on dips for investors comfortable with elevated volatility in exchange for disruptive potential.

QQQ (Invesco QQQ ETF) The Nasdaq-100 tracker continues its strong run, recently hitting all-time highs near $738 with YTD gains exceeding 20%. Heavy exposure to leading AI and tech names makes QQQ the premier vehicle for capturing broad innovation leadership. We recommend it as a core growth holding in any diversified portfolio.

IWM (iShares Russell 2000 ETF) Small caps have outperformed in 2026 with IWM up nearly 19% YTD, benefiting from lower rates, earnings acceleration, and domestic economic resilience. The Russell 2000 offers attractive valuations and higher projected growth versus large caps. We add IWM for diversification and exposure to the ongoing small-cap rotation.

GS (Goldman Sachs) Goldman Sachs is well-positioned amid buoyant M&A volumes and strong investment banking activity. The firm benefits from resilient consumer trends, higher market activity, and its leading role in major deals. With solid earnings power and a healthy dividend, GS provides financial sector exposure with cyclical upside.

LLY (Eli Lilly) Eli Lilly stands out in healthcare with powerful obesity and oncology pipelines. Recent Phase 3 success for Retevmo in lung cancer, strong Mounjaro/Zepbound demand, and multiple acquisitions in vaccines underscore its growth trajectory. Management has raised 2026 guidance, making LLY a cornerstone long-term healthcare recommendation.